Table 5.

Percentages of complete response, partial response, and failure to IL-1 inhibition, based on previous biologic therapies.

Totality of treatments (526)	Type of response	0 previous biologics (362/526)	1 previous biologic (92/526)	2 previous biologics (40/526)	3 previous biologics (17/526)	4 previous biologics (9/256)	≥5 previous biologics (6/256)
	Complete	243/362 (67.12%)ab	53/92 (57.60%)cd	14/40 (35%)ac	3/17 (17.64%)bd	4/9 (44.44%)	2/6 (33.33%)
	Partial	83/362 (22.92%)ef	32/92 (34.78%)	19/40 (47.5%)e	10/17 (58.82%)f	3/9 (33.33%)	2/6 (33.33%)
	Failure	36/362 (9.94%)	7/92 (7.60%)	7/40 (17.5%)	4/17 (23.52%)	2/9 (22.22%)	2/6 (33.33%)
Totality of treatments (Anakinra) (421)	Type of response	0 previous biologics (323/421)	1 previous biologic (52/421)	2 previous biologics (28/421)	3 previous biologics (8/421)	4 previous biologics (5/421)	≥5 previous biologics (5/421)
	Complete	219/323 (67.80%)ghi	21/52 (40.38%)g	10/28 (35.71%)h	2/8 (25%)i	2/5 (40%)	2/5 (40%)
	Partial	72/323 (22.29%)lmn	25/52 (48.07%)l	13/28 (46.42%)m	4/8 (50%)n	1/5 (20%)	1/5 (20%)
	Failure	32/323 (9.90%)	6/52 (11.53%)	5/28 (17.85%)	2/8 (25%)	2/5 (40%)°	2/5 (40%)
Totality of treatments (Canakinumab) (105)	Type of response	0 previous biologics (37/105)	1 previous biologic (42/105)	2 previous biologics (12/105)	3 previous biologics (9/105)	4 previous biologics (4/105)	≥5 previous biologics (1/105)
	Complete	23/37 (62.16%)	33/42 (78.57%)op	4/12 (33.33%)o	2/9 (22.22%)	2/4 (50%)	0/1 (0%)
	Partial	10/37 (27.02%)q	8/42 (19.04%)rs	6/12 (50%)r	6/9 (66.66%)qs	2/4 (50%)	1/1 (100%)
	Failure	4/37 (10.81%)	1/42 (2.38%)	2/12 (16.66%)	1/9 (11.11%)	0/4 (0%)	0/1 (0%)

^ap = 0.0001,

^bp < 0.0001,

^cp = 0.02,

^dp = 0.0031,

^ep = 0.001,

^fp = 0.002,

^gp = 0.0003,

^hp = 0.001,

ⁱp = 0.0181,

^lp = 0.0002,

^mp = 0.009,

ⁿp = 0.0850,

^op = 0.005,

^pp = 0.002,

^qp = 0.04,

^rp = 0.0573,

^sp = 0.008.